IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: Further clinical studies of DAB389-IL2, including a phase III clinical study on 71 patients with biopsy-proven CTCL expressing the IL-2R (Olsen et al., 2001; Duvic et al., 2002) led to its approval by the FDA for the treatment of persistent or recurrent CTCL under the name denileukin diftitox (ONTAKTM) in 2008.